previous
develop
respiratori
tract
vaccin
ebola
viru
ebov
base
human
parainfluenza
viru
type
respiratori
paramyxoviru
express
ebov
gp
envelop
protein
ad
gene
two
dose
vaccin
deliv
intranas
intratrach
rout
protect
monkey
intraperiton
challeng
ebov
howev
concern
exist
vaccin
may
reduc
immunogen
adult
human
popul
due
preexist
immun
develop
new
vaccin
ndv
gp
base
newcastl
diseas
viru
ndv
avian
paramyxoviru
antigen
distinct
human
viral
pathogen
highli
attenu
monkey
follow
one
intranas
intratrach
inocul
rhesu
monkey
ndvgp
titer
ebovspecif
antibodi
respiratori
tract
secret
serum
sampl
determin
elisa
well
serum
ebovneutr
antibodi
undetect
low
compar
induc
second
immun
result
substanti
boost
serum
igg
elisa
titer
yet
titer
remain
lower
induc
second
dose
contrast
elisa
iga
titer
respiratori
tract
secret
importantli
serum
ebovneutr
antibodi
titer
equal
induc
second
dose
data
suggest
ndvgp
effect
immun
ebov
alon
combin
either
anoth
vaccin
platform
heterolog
primeboost
regimen
ebola
viru
ebov
caus
sever
hemorrhag
fever
human
fatal
rate
speci
zair
infect
individu
current
licens
vaccin
viru
continu
period
outbreak
central
africa
potenti
use
bioterror
necessit
develop
earli
attempt
develop
vaccin
base
inactiv
virus
purifi
antigen
unsuccess
recent
studi
suggest
feasibl
approach
base
viral
vector
viruslik
particl
develop
paramyxovirusbas
viral
vector
immun
common
respiratori
virus
well
highli
pathogen
emerg
virus
includ
ebov
review
ebov
readili
initi
infect
contact
mucos
surfac
might
advantag
use
vector
natur
tropism
respiratori
tract
elicit
local
antibodi
respons
site
well
robust
system
immun
respons
therefor
evalu
paramyxovirus
infect
respiratori
tract
vaccin
vector
paramyxovirus
singl
nonseg
negativesens
rna
genom
paramyxovirus
present
studi
approxim
kb
length
contain
six
gene
transcrib
individu
mrna
sequenti
transcript
initi
end
guid
genestart
geneend
transcript
signal
flank
gene
replic
involv
fulllength
positivesens
intermedi
call
antigenom
foreign
protein
readili
express
engin
code
sequenc
flank
genestart
geneend
sequenc
follow
insert
viral
genom
result
replic
compet
vector
express
foreign
gene
separ
mrna
strategi
follow
present
studi
second
strategi
other
pursu
studi
replac
vector
surfac
protein
pathogen
interest
result
chimer
virus
initi
evalu
human
parainfluenza
viru
type
common
respiratori
tract
pathogen
vector
ebov
found
two
dose
express
surfac
glycoprotein
gp
ebov
addit
gene
origin
refer
refer
deliv
combin
intranas
intratrach
rout
complet
protect
rhesu
monkey
intraperiton
challeng
highli
lethal
dose
ebov
potenti
drawback
approach
major
adult
human
popul
preexist
immun
due
natur
exposur
may
neutral
vaccin
thu
reduc
immunogen
exampl
preexist
immun
result
reduc
immunogen
vector
vaccin
candid
base
vaccinia
viru
human
adenoviru
type
includ
vaccin
ebov
base
human
adenovir
vector
concern
may
hold
sinc
two
dose
regimen
appear
equal
immunogen
either
naiv
monkey
nonetheless
also
investig
newcastl
diseas
viru
ndv
avian
paramyxoviru
antigen
distinct
common
human
pathogen
altern
human
vaccin
vector
ndv
strain
categor
three
pathotyp
base
diseas
sever
bird
lentogen
strain
viru
caus
asymptomat
mild
infect
respiratori
alimentari
tract
bird
mesogen
strain
caus
infect
intermedi
sever
velogen
strain
caus
sever
infect
associ
high
mortal
previous
demonstr
ndv
highli
attenu
respiratori
tract
nonhuman
primat
due
hostrang
restrict
replic
also
show
init
immun
nonhuman
primat
recombin
ndvbase
vaccin
respiratori
pathogen
sever
acut
respiratori
syndrom
associ
coronaviru
highli
pathogen
avian
influenza
viru
protect
challeng
respect
virus
present
studi
extend
approach
gener
recombin
ndv
express
gp
ebov
ndvgp
therebi
repres
first
attempt
use
ndvvector
vector
immun
system
rather
respiratori
human
pathogen
assess
immunogen
ndvgp
nonhuman
primat
model
follow
init
administr
vaccin
parallel
previous
character
vaccin
vector
two
ndv
strain
use
make
construct
express
ebov
gp
name
beaudett
c
lasota
vf
construct
beaudett
cbase
vaccin
viru
open
read
frame
ebovzair
mayinga
strain
gp
previou
construct
amplifi
use
pcr
primer
design
flank
upstream
side
ndv
gene
junction
includ
genestart
geneend
sequenc
intergen
region
cdna
also
flank
side
xbai
site
primer
also
design
ensur
final
antigenom
cdna
ndvgp
would
conform
rule
six
wherebi
genom
nucleotid
length
even
multipl
six
order
effici
rna
replic
occur
ebov
gp
pcr
product
clone
xbai
site
previous
creat
untransl
region
downstream
p
open
read
frame
cdna
encod
fulllength
antigenom
strain
beaudett
c
fig
backbon
second
xbai
site
origin
present
l
open
read
frame
disabl
introduct
two
silent
nucleotid
substitut
use
quickchang
xl
site
direct
mutagenesi
kit
agil
technolog
santa
clara
ca
construct
place
insert
gp
code
sequenc
set
ndv
transcript
signal
posit
ndv
genom
p
gene
lasota
vfbase
construct
made
replac
genom
cdna
subclon
strain
lasota
xbai
site
insert
place
strain
beaudett
c
follow
insert
ebovgp
pcr
produc
recoveri
amplif
titrat
two
recombin
ndv
perform
describ
previous
ndv
ndvgp
construct
propag
chicken
embryo
fibroblast
cell
monolay
dmem
medium
invitrogen
carlsbad
ca
supplement
fetal
bovin
serum
mm
lglutamin
titrat
plaqu
assay
previous
describ
construct
propag
rhesu
monkey
kidney
cell
monolay
optimem
medium
invitrogen
supplement
fetal
bovin
serum
mm
lglutamin
titrat
either
plaqu
assay
immunostain
previous
describ
limit
dilut
cell
monolay
gp
recombin
vesicular
stomat
viru
express
ebov
gp
sole
surfac
glycoprotein
provid
dr
h
feldmann
nation
institut
allergi
infecti
diseas
propag
vero
african
green
monkey
kidney
cell
monolay
optipro
medium
invitrogen
supplement
mm
glutamin
titrat
limit
dilut
vero
cell
monolay
limit
dilut
titrat
infect
score
base
visual
assess
cytopath
effect
titer
calcul
use
method
reed
muench
express
tissu
cultur
infecti
dose
tcid
ml
confirm
express
ebov
gp
cell
infect
ndvgp
vaccin
construct
multipl
infect
moi
plaqu
form
unit
pfu
per
cell
cell
lysat
collect
h
post
infect
subject
sdspage
denatur
reduc
condit
analyz
western
blot
describ
previous
guinea
pig
serum
specif
ebov
gp
sgp
provid
dr
sanchez
center
diseas
control
prevent
atlanta
ga
chicken
polyclon
antibodi
rais
ndv
charl
river
laboratori
wilmington
use
primari
antibodi
horseradish
peroxidaselabel
goat
antibodi
specif
guinea
pig
chicken
igg
jackson
immunoresearch
laboratori
west
grove
pa
use
secondari
antibodi
evalu
whether
ebov
gp
incorpor
ndvgp
viral
particl
lasota
vfvector
vaccin
viru
purifi
sucros
gradient
previous
describ
analyz
western
blot
reduc
denatur
condit
adult
rhesu
monkey
macaca
mulatta
obtain
morgan
island
sc
confirm
seroneg
ndv
hemagglutin
inhibit
hai
assay
use
turkey
guinea
pig
erythrocyt
respect
previous
describ
day
anim
inocul
init
rout
pfu
per
site
beaudett
cbase
ndvgp
monkey
monkey
previous
describ
day
anim
receiv
second
inocul
ident
initi
inocul
tracheal
lavag
tl
nasal
wash
nw
sampl
collect
indic
time
point
previous
describ
assess
mucos
iga
respons
vaccin
shed
serum
sampl
collect
indic
time
point
assess
immun
respons
serum
ebovspecif
iga
igg
serum
igg
titer
avid
determin
elisa
previous
describ
use
purifi
gammairradi
ebovzair
kindli
provid
dr
anthoni
sanchez
antigen
mucos
ebovspecif
iga
nw
tl
analyz
elisa
previous
describ
use
ebov
antigen
ebov
gpspecif
serum
neutral
antibodi
analyz
ebov
gp
previous
describ
analyz
cellular
immun
respons
pbmc
isol
day
previous
describ
immedi
cryopreserv
time
point
collect
cell
thaw
stimul
overnight
pool
peptid
mimotop
clayton
victoria
australia
span
entir
ebov
gp
sequenc
consist
residu
overlap
adjac
peptid
final
composit
cell
stimul
reaction
pbmc
mm
peptid
bd
bioscienc
san
jose
ca
bd
bioscienc
golgiplug
bd
bioscienc
final
volum
follow
stimul
cell
fix
permeabil
stain
use
cytofixcytoperm
system
bd
bioscienc
cell
stain
optim
dilut
follow
antibodi
bd
bioscienc
antihuman
label
fluorescein
isotyocyan
antihuman
label
peridininchlorophyl
antihuman
label
phycoerythrin
either
antihuman
label
allophycocyanin
similarli
label
antihuman
flow
cytometri
perform
use
facscalibur
flow
cytomet
bd
bioscienc
analysi
perform
use
flowjo
version
softwar
tree
star
inc
ashland
two
ndv
strain
use
make
construct
express
ebov
gp
mesogen
strain
beaudett
c
produc
infecti
viru
vitro
without
need
ad
trypsin
ii
strain
lasota
vf
version
lentogen
strain
lasota
f
protein
cleavag
site
replac
beaudett
c
order
elimin
requir
exogen
proteas
produc
infecti
viru
tissu
cultur
construct
open
read
frame
ebov
gp
place
control
set
ndv
genestart
geneend
transcript
signal
insert
ndv
genom
ad
gene
p
gene
fig
describ
previous
gp
code
sequenc
modifi
introduct
two
silent
mutat
edit
site
contain
eight
consecut
residu
result
increas
gene
stabil
paramyxoviru
vector
ndvgp
construct
recov
previous
describ
amplifi
chicken
fibroblast
cell
integr
gp
insert
confirm
sequenc
gp
express
confirm
western
blot
analysi
cell
infect
virus
data
shown
present
studi
lasota
vfbase
construct
use
one
experi
investig
incorpor
ebov
gp
ndv
particl
fig
experi
pathotyp
differ
irrelev
beaudett
cbase
construct
use
experi
involv
immun
nonhuman
primat
worth
note
previous
show
strain
beaudett
c
lasota
lasota
vf
similarli
attenu
immunogen
vector
nonhuman
primat
hereaft
distinguish
beaudett
cbase
lasota
vfbase
construct
refer
ndvgp
foreign
transmembran
envelop
protein
encod
nonseg
neg
strand
virus
may
may
incorpor
recombin
viral
particl
incorpor
thought
desir
properti
increas
immunogen
although
clearli
demonstr
previous
show
ebov
gp
express
incorpor
particl
case
recombin
ndvvector
vaccin
incorpor
foreign
protein
detect
case
determin
whether
gp
incorpor
ndvgp
viral
particl
preform
western
blot
analysi
purifi
strain
lasota
vfbase
ndvgp
virion
fig
ebov
gp
type
transmembran
protein
cleav
two
disulphidelink
subunit
found
ebov
gp
particl
aminotermin
kda
contain
ectodomain
kda
contain
transmembran
domain
cytoplasm
tail
purifi
ndvgp
particl
easili
detect
abund
speci
mr
kda
fig
detect
antiebov
guinea
pig
serum
use
analysi
consist
previou
studi
data
suggest
ebov
gp
incorpor
vaccin
viru
particl
four
rhesu
monkey
anim
number
immun
combin
init
rout
pfu
per
site
ndvgp
also
immun
addit
two
monkey
rout
pfu
per
site
previous
shown
protect
complet
lethal
ebov
challeng
thu
provid
posit
control
predict
potenti
protect
efficaci
ndvbase
vaccin
day
monkey
given
second
dose
respect
vaccin
immun
monkey
exhibit
sign
clinic
ill
due
vaccin
order
evalu
replic
vaccin
construct
collect
tl
nw
sampl
day
initi
immun
assay
infecti
vaccin
viru
littl
shed
detect
immun
ndvgp
tabl
consist
previou
studi
contrast
consist
previou
studi
gpimmun
monkey
demonstr
substanti
viru
shed
upper
lower
respiratori
tract
time
point
test
data
indic
ndvgp
substanti
attenu
respiratori
tract
monkey
initi
test
vectorspecif
serum
antibodi
respons
immun
monkey
ndvspecif
hai
fig
b
monkey
immun
ndvgp
develop
substanti
ndvspecif
serum
hai
antibodi
respons
fig
day
follow
first
dose
mean
serum
hai
titer
ndv
substanti
lower
induc
twentyeight
day
follow
second
dose
day
ndvspecif
antibodi
titer
increas
still
lower
induc
day
clear
directli
valu
ndvand
hpivspecif
hai
assay
compar
lower
level
vectorspecif
antibodi
induc
ndvgp
compar
consist
highli
restrict
replic
ndvgp
respiratori
tract
monkey
tabl
sinc
uvinactiv
deliv
respiratori
tract
poorli
immunogen
immunogen
like
ndvgp
depend
replic
respiratori
tract
therefor
increas
vectorspecif
antibodi
respons
follow
second
dose
suggest
replic
ndvand
vector
occur
despit
vectorspecif
immun
induc
first
dose
analyz
local
antibodi
respons
ebov
gp
test
gpspecif
iga
antibodi
titer
respiratori
tract
secret
immun
monkey
nw
tl
sampl
concentr
gpspecif
iga
antibodi
titer
determin
isotypespecif
elisa
detect
substanti
ebov
gpspecif
antibodi
titer
nw
sampl
monkey
first
second
dose
shown
howev
abl
detect
tl
sampl
fig
twentyeight
day
first
dose
gpspecif
iga
antibodi
detect
one
four
ndvgpimmun
monkey
one
two
monkey
second
dose
day
monkey
detect
gpspecif
iga
tl
mean
titer
ndvgpimmun
anim
anim
fig
also
normal
gpspecif
iga
total
iga
respiratori
secret
determin
elisa
result
similar
iga
valu
two
vaccin
fig
analysi
also
show
detect
gpspecif
elisa
titer
independ
total
iga
content
sampl
ie
sampl
undetect
gpspecif
iga
high
total
iga
content
demonstr
specif
gp
elisa
result
suggest
respiratori
tract
immun
ndvgp
induc
local
antibodi
respons
respiratori
tract
level
compar
achiev
follow
vaccin
antibodi
may
play
import
role
protect
aerosol
exposur
ebov
next
assess
serum
antibodi
respons
ebov
gp
fig
comparison
includ
three
addit
sera
anim
fig
b
previous
publish
studi
monkey
immun
ident
current
studi
demonstr
complet
protect
subsequ
lethal
ebov
challeng
four
ndvgpimmun
monkey
detect
gpspecif
igg
titer
follow
initi
vaccin
dose
boost
follow
second
dose
fig
howev
titer
somewhat
lower
monkey
immun
time
point
test
rang
versu
respect
initi
immun
day
sera
versu
respect
secondari
immun
day
sera
also
assess
qualiti
antibodi
respons
analyz
avid
ebov
gpspecif
serum
antibodi
fig
found
first
dose
ndvgp
avid
much
lower
seen
first
dose
follow
second
dose
gpspecif
antibodi
avid
ndvgp
immun
monkey
significantli
increas
becam
close
observ
vaccin
sinc
day
sera
onedos
group
remain
unknown
whether
increas
avid
associ
administr
second
dose
repres
continu
affin
matur
time
previou
studi
monkey
given
one
two
dose
ndvvector
vaccin
highli
pathogen
influenza
viru
demonstr
continu
increas
avid
time
onedos
monkey
enhanc
monkey
receiv
two
dose
determin
neutral
activ
ebov
gpspecif
serum
antibodi
employ
neutral
assay
use
recombin
vsv
endogen
glycoprotein
gene
replac
gp
gene
ebov
result
chimer
viru
gp
whose
viral
envelop
glycoprotein
ebov
gp
infect
viru
complet
depend
ebov
gp
make
use
surrog
ebov
neutral
use
biosafeti
level
condit
includ
sera
two
addit
anim
monkey
fig
immun
manner
current
studi
two
anim
monkey
distinct
sera
includ
elisa
analysi
monkey
due
limit
remain
suppli
sera
first
dose
vaccin
four
ndvgpimmun
monkey
larg
undetect
neutral
antibodi
respons
four
monkey
demonstr
detect
level
neutral
antibodi
mean
fig
howev
second
dose
ndvgp
substanti
level
neutral
antibodi
detect
close
observ
monkey
receiv
two
dose
thu
despit
greater
attenu
ndvgp
replic
respiratori
tract
compar
two
vector
induc
compar
titer
ebovneutr
serum
antibodi
follow
two
immun
also
analyz
cellular
immun
respons
peripher
blood
variou
time
point
postimmun
pbmc
first
stimul
overlap
peptid
pool
span
entir
ebov
gp
protein
cell
stain
cell
marker
either
surfac
molecul
follow
intracellular
stain
cytokin
marker
cell
activ
detect
substanti
number
cell
specif
secret
either
cytokin
shown
howev
detect
gpspecif
cell
respons
one
ndvgpimmun
anim
monkey
day
total
cell
secret
respect
anim
also
demonstr
respons
day
day
second
vaccin
cell
secret
respect
fig
b
anoth
ndvgpimmun
anim
monkey
appear
rel
high
percentag
cell
secret
day
cell
day
second
vaccin
cell
howev
anim
also
high
background
day
studi
interestingli
two
anim
immun
demonstr
lower
percentag
cell
posit
slightli
higher
day
background
level
low
level
virusspecif
cell
peripher
blood
consist
low
level
cell
elicit
monkey
ndvvector
vaccin
sever
acut
respiratori
syndromeassoci
coronaviru
highli
pathogen
avian
influenza
viru
well
previou
studi
previou
vaccin
test
immun
anim
protect
infect
respect
virus
indic
detect
gpspecif
cellmedi
respons
peripher
blood
essenti
indic
vaccin
efficaci
low
cellular
respons
detect
peripher
blood
may
account
observ
follow
infect
human
respiratori
virus
major
virusspecif
cell
locat
lung
rather
peripher
blood
current
studi
develop
new
respiratori
tract
vaccin
ebov
base
ndv
vector
evalu
replic
immunogen
monkey
comparison
previous
develop
respiratori
tract
vaccin
two
dose
demonstr
complet
protect
lethal
ip
challeng
ebov
monkey
addit
wildtyp
attenu
replic
asymptomat
nonhuman
primat
reflect
host
rang
differ
human
viru
thu
provid
benchmark
attenu
vector
found
ndvbase
vaccin
much
attenu
replic
respiratori
tract
monkey
compar
vector
fig
furthermor
test
first
time
ebovspecif
mucos
antibodi
respons
respiratori
tract
found
ndvgp
induc
detect
titer
ebovspecif
iga
lower
respiratori
tract
mostli
second
dose
similar
titer
elicit
anim
immun
fig
also
detect
ebov
gpspecif
elisa
antibodi
peripher
blood
albeit
level
lower
monkey
despit
attenu
ndvgp
replic
lower
titer
ebovspecif
elisa
serum
antibodi
induc
ndvgp
compar
level
ebovspecif
neutral
serum
antibodi
ndvgp
immun
monkey
equal
monkey
fig
moreov
immun
ndvgp
induc
detect
ebovspecif
cell
peripher
blood
appear
induc
ebov
gpspecif
cell
secret
andor
anim
fig
also
induc
margin
increas
ebov
gpspecif
cell
monkey
detect
day
studi
consist
find
previou
report
vaccin
candid
alreadi
mention
rel
low
cellmedi
respons
detect
peripher
blood
like
reflect
preferenti
accumul
cell
pulmonari
site
immun
rather
peripher
blood
design
present
studi
preclud
analysi
cellmedi
respons
lung
tissu
euthanasia
monkey
requir
import
perform
analys
futur
level
immun
respons
induc
ndvgp
protect
challeng
ebov
note
two
dose
deliv
combin
inocul
pfu
per
site
complet
protect
rhesu
monkey
ip
challeng
pfu
ebov
previou
studi
new
ndvgp
vaccin
base
respiratori
paramyxoviru
although
one
natur
infect
bird
rather
human
sinc
two
dose
ndvgp
induc
substanti
titer
ebov
gpspecif
serum
elisa
antibodi
importantli
ebovneutr
antibodi
level
equal
observ
two
dose
vaccin
candid
like
compar
term
protect
ebov
challeng
challeng
ndvgpimmun
anim
present
studi
facil
avail
time
evalu
futur
second
dose
significantli
boost
ebovspecif
antibodi
respons
requir
uniform
complet
protect
ebov
challeng
suggest
vectorspecif
respons
first
dose
reduc
complet
restrict
replic
second
dose
vector
anim
vectorspecif
immun
preclud
boost
secondari
immun
respons
might
substanti
effect
vectorspecif
immun
circumv
exampl
use
serolog
distinct
vsv
vector
primari
secondari
immun
human
immunodefici
significantli
improv
respons
vaccin
mice
induc
highli
potent
immun
respons
monkey
studi
date
result
develop
three
distinct
respiratori
tract
vaccin
candid
ebov
name
use
posit
control
present
studi
ii
version
hemagglutininneuraminidas
fusion
glycoprotein
neutral
antigen
vector
delet
iii
ndvgp
develop
present
studi
thu
three
vector
provid
basi
primari
secondari
immun
use
antigen
distinct
paramyxoviru
vector
result
potent
respons
ebov
gp
induc
homolog
primeboost
regimen
could
provid
effect
protect
ebov
challeng
ultim
comparison
variou
vaccin
regimen
involv
sequenti
administr
three
vaccin
use
variou
combin
two
differ
construct
primari
secondari
vaccin
identifi
effect
regimen
vaccin
ndvgp
viru
purifi
sucros
gradient
analyz
sdspage
western
blot
comparison
empti
ndv
vector
left
panel
antindv
polyclon
antibodi
use
detect
ndv
hn
np
cleavag
product
f
protein
right
panel
ebov
gpspecif
antibodi
use
detect
kda
protein
gener
posttransl
cleavag
fulllength
gp
protein
serum
vectorspecif
antibodi
respons
determin
hai
assay
use
turkey
erythrocyt
ndvspecif
antibodi
b
guinea
pig
erythrocyt
antibodi
individu
valu
monkey
well
group
mean
horizont
line
plot
limit
detect
log
indic
dot
line
sera
titer
detect
limit
assign
titer
log
calcul
mean
ebov
gpspecif
serum
antibodi
respons
individu
valu
sampl
well
group
mean
horizont
line
plot
ebov
gpspecif
serum
igg
titer
determin
monkey
current
studi
ndvgp
red
circl
black
triangl
well
addit
monkey
number
previous
immun
ident
monkey
current
studi
shown
complet
protect
ebov
challeng
limit
detect
log
dot
line
b
avid
ebovspecif
serum
igg
ebovspecif
reactiv
given
serum
sampl
compar
urea
wash
use
modif
previous
report
method
residu
reactiv
follow
wash
express
percentag
reactiv
prior
wash
one
histor
sampl
day
monkey
exclud
analysi
due
limit
quantiti
serum
c
ebovspecif
serum
neutral
titer
sera
two
addit
monkey
number
distinct
b
also
immun
ident
current
studi
includ
analysi
limit
detect
log
dot
line
statist
signific
assay
calcul
use
anova
bonferroni
posttest
p
p
p
symbol
directli
data
set
repres
statisticl
signific
rel
previou
time
point
symbol
horizont
cap
line
indic
statist
signific
indic
group
ebov
gpspecif
cell
respons
detect
peripher
blood
sampl
follow
vaccin
pbmc
variou
time
point
stimul
peptid
pool
span
entir
ebov
gp
protein
presenc
golgiplug
brefeldin
stain
surfac
cell
marker
cell
fix
permeabil
stain
intracellular
accumul
b
indic
activ
detect
accumul
either
cytokin
cell
shown
